68Ga-PSMA-11 PET/CT 用于新诊断前列腺癌:前列腺内 PSMA 摄取与多项临床参数的相关性
纳入104例新诊断、未治疗的前列腺癌男性,测量健康前列腺组织与恶性前列腺病灶的 SUVmax 并比较 PSA、Gleason 评分和 d'Amico 风险分类。健康组织平均 SUVmax 为1.88±0.44,恶性病灶为10.77±8.45(P<0.001);PSA、GS、d'Amico 风险越高,PSMA 摄取越高(各 P<0.001)。
要点
- 健康前列腺组织平均 SUVmax 1.88±0.44,恶性前列腺病灶 10.77±8.45,差异有统计学意义(P<0.001)。
- PSA 更高、GS 更高、d'Amico 风险评分更高的患者,PSMA PET/CT 摄取有统计学显著升高(各 P<0.001)。
- 作者认为 PSMA PET/CT 适合检出初诊前列腺癌的前列腺内恶性病灶。
核心结论
- 作者认为 PSMA PET/CT 适合检测新诊断前列腺癌患者的前列腺内恶性病灶。
- 作者指出 PSMA 摄取与 PSA、GS 及 d'Amico 风险分类存在显著相关性。
研究设计与样本
- 纳入104例新诊断前列腺癌、未接受过治疗的男性。
- 测量 SUVmax 并与活检结果及 MRI 进行关联,随后与当前 PSA 值、GS 和 d'Amico 风险分类比较。
主要发现
- 健康前列腺组织平均 SUVmax 为1.88±0.44,恶性前列腺病灶为10.77±8.45(P<0.001)。
- PSA 更高、GS 更高、d'Amico 风险评分更高的患者,PSMA PET/CT 摄取有统计学显著升高(各 P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a promising diagnostic tool for patients with prostate cancer. Our study evaluates SUVs in benign prostate tissue and malignant, intraprostatic tumor lesions and correlates results with several clinical parameters. Methods: One hundred four men with newly diagnosed prostate carcinoma and no previous therapy were included in this study. SUVmax was measured and correlated with biopsy findings and MRI. Afterward, data were compared with current prostate-specific antigen (PSA) values, Gleason score (GS), and d'Amico risk classification. Results: In this investigation a mean SUVmax of 1.88 ± 0.44 in healthy prostate tissue compared with 10.77 ± 8.45 in malignant prostate lesions (P < 0.001) was observed. Patients with higher PSA, higher GS, and higher d'Amico risk score had statistically significant higher PSMA uptake on PET/CT (P < 0.001 each). Conclusion: PSMA PET/CT is well suited for detecting the intraprostatic malignant lesion in patients with newly diagnosed prostate cancer. Our findings indicate a significant correlation of PSMA uptake with PSA, GS, and risk classification according to the d'Amico scale.
引用
- Koerber SA, Utzinger MT, Kratochwil C, et al. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. J Nucl Med. 2017. PMID: 28619734. doi:10.2967/jnumed.117.190314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。